A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non‐Alcoholic Fatty Liver Disease

2019 ◽  
Vol 63 (20) ◽  
pp. 1900487 ◽  
Author(s):  
Petar Dianov Petrov ◽  
Maria Victoria García‐Mediavilla ◽  
Carla Guzmán ◽  
David Porras ◽  
Esther Nistal ◽  
...  
Keyword(s):  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Bile Acids ◽  
Fatty Liver Disease ◽  
Hepatic Metabolism ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease

2017 ◽  
Vol 35 (3) ◽  
pp. 282-287 ◽  
Author(s):  
Daniel Steinacher ◽  
Thierry Claudel ◽  
Michael Trauner
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Ursodeoxycholic Acid ◽  
Bile Acids ◽  
Fatty Liver Disease ◽  
Liver Diseases ◽  
Hepatic Metabolism ◽  
Alcoholic Fatty Liver ◽  
New Class ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease is one of the most rapidly rising clinical problems in the 21st century. So far no effective drug treatment has been established to cure this disease. Bile acids (BAs) have a variety of signaling properties, which can be used therapeutically for modulating hepatic metabolism and inflammation. A side-chain shorted derivative of ursodeoxycholic acid (UDCA) is 24 nor-ursodeoxycholic acid (NorUDCA) and it represents a new class of drugs for treatment of liver diseases. NorUDCA has unique biochemical and therapeutic properties, since it is relatively resistant to conjugation with glycine or taurine compared to UDCA. NorUDCA undergoes cholehepatic shunting, resulting in ductular targeting, bicarbonate-rich hypercholeresis, and cholangiocyte protection. Furthermore, it showed anti-fibrotic, anti-inflammatory, and anti-lipotoxic properties in several animal models. As such, NorUDCA is a promising new approach in the treatment of cholestatic and metabolic liver diseases. This review is a summary of current BA-based therapeutic approaches in the treatment of the fatty liver disease.

scholarly journals Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review

Foods ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 1719
Author(s):  
Valentina Castillo ◽  
Fernanda Figueroa ◽  
Karoll González-Pizarro ◽  
Paz Jopia ◽  
Claudia Ibacache-Quiroga
Keyword(s):  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Communicable Disease ◽  
Anthropometric Parameters ◽  
Alcoholic Fatty Liver ◽  
Risks Factors ◽  
Alcoholic Fatty Liver Disease ◽  
Non Communicable Disease

Non-alcoholic fatty liver disease (NAFLD) is a chronic non-communicable disease, with a prevalence of 25% worldwide. This pathology is a multifactorial illness, and is associated with different risks factors, including hypertension, hyperglycemia, dyslipidemia, and obesity. Beside these predisposing features, NAFLD has been related to changes in the microbiota, which favor the disease progression. In this context, the modulation of the gut microbiota has emerged as a new therapeutic target for the prophylaxis and treatment of NAFLD. This review describes the changes in the gut microbiota associated with NAFLD and the effect of probiotics, prebiotics, and synbiotics on the gut microbiota, liver damage, anthropometric parameters, blood lipids, inflammation markers and insulin resistance in these patients.

Gut microbiota and non-alcoholic fatty liver disease: a narrative review

2021 ◽  
Author(s):  
Ludovico Abenavoli ◽  
Anna C. Procopio ◽  
Emidio Scarpellini ◽  
Natale Polimeni ◽  
Isabella Aquila ◽  
...  
Keyword(s):  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Narrative Review ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Correlation of Gut Firmicutes/Bacteroidetes Ratio with Fibrosis and Steatosis in Patients with Non-alcoholic Fatty Liver Disease

2020 ◽  
Author(s):  
Chyntia Olivia Maurine Jasirwan ◽  
Akhmadu Muradi ◽  
Irsan Hasan ◽  
Marcellus Simadibrata ◽  
Ikhwan Rinaldi ◽  
...  
Keyword(s):  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Central Obesity ◽  
Gastrointestinal Microbiota ◽  
Alcoholic Fatty Liver ◽  
Microbiota Diversity ◽  
Alcoholic Fatty Liver Disease ◽  
High Triglyceride

Abstract Background : We investigated the gut microbiota in patients with non-alcoholic fatty liver disease (NAFLD) and its correlation with fibrosis and steatosis as reflected in the controlled attenuation parameter and transient elastography valuesMethods : A cross-sectional study was performed on 37 patients with NAFLD at Cipto Mangunkusumo National General Hospital from December 2018 to March 2019. The gut microbiota was investigated in fecal samples with 16S RNA sequencing using the next-generation sequencing platform MiSeq (Illumina).Results : NAFLD was more common in patients with metabolic syndrome. Firmicutes, Bacteroidetes, and Proteobacteria were the predominant phyla. Bacteroides was more dominant than Prevotella, contrary to the results in previous studies on normal populations in Indonesia. Microbiota dysbiosis was observed in most samples. The gastrointestinal microbiota diversity was significantly decreased in patients with NAFLD with high triglyceride levels and central obesity. The Firmicutes/Bacteroidetes ratio correlated with steatosis and obesity, whereas some other species in the lower taxonomy were mostly correlated with steatosis and obesity without fibrosis. Proteobacteria is the only phylum strongly correlated with fibrosis in patients with normal body mass index.Conclusions : The gut microbiota diversity was decreased in patients with NAFLD with high triglyceride levels and central obesity, and certain gut microbes were correlated with fibrosis and steatosis.

Sign in / Sign up

Export Citation Format

Share Document